Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 225
- Registration Number
- NCT02308527
- Locations
- 🇦🇹
St Anna Children's Hospital and CCRI/Studies and Statistics, Vienna, Austria
🇩🇰University Hospital Rigshospitalet, Copenhagen, Denmark
🇮🇹Ospedale Pediatrico Bambino Gseu, Rome, Italy
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2024-02-09
- Target Recruit Count
- 18
- Registration Number
- NCT02298348
- Locations
- 🇺🇸
Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Michael Vogelbaum, MD, PhD
- Target Recruit Count
- 3
- Registration Number
- NCT02278510
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT02200757
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
🇺🇸Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸Oncology Hermatology Care, Inc., Cincinnati, Ohio, United States
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT02114229
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸Lucille Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 260
- Registration Number
- NCT02101788
- Locations
- 🇺🇸
Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States
🇺🇸Saint Joseph Hospital East, Lexington, Kentucky, United States
🇺🇸Saint Joseph London, London, Kentucky, United States
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02100007
- Locations
- 🇬🇧
The Bays St Mary's Hospital, London, England, United Kingdom
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2024-02-09
- Target Recruit Count
- 30
- Registration Number
- NCT02030964
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇦🇺Sydney Childrens Hospital KCC, Randwick, Australia
🇺🇸Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT01931098
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Therapy for Children With Advanced Stage Neuroblastoma
- Conditions
- Interventions
- Drug: cyclophosphamideDrug: topotecanBiological: hu14.18K322AProcedure: peripheral blood stem cell harvestProcedure: surgical resectionDrug: cisplatinDrug: etoposideDrug: doxorubicinDrug: vincristineDrug: busulfanDrug: melphalanBiological: peripheral blood stem cell transplantationBiological: natural killer cell infusionRadiation: radiation therapyBiological: GM-CSFBiological: G-CSFDrug: mesnaDrug: levetiracetamBiological: interleukin-2Drug: IsotretinoinDevice: CliniMACS
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 153
- Registration Number
- NCT01857934
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.